01 December 2005
The effects of non-selective and cyclooxygenase-2-selective non-steroidal anti-inflammatory drugs on heterotopic ossification in rats.
Nergiz Murat, Nil Hocaoglu, Vasfi Karatosun, Kutsal Yorukoglu, Sedef Gidener, Izge GunalMed Sci Monit 2005; 11(12): BR449-451 :: ID: 438847
Abstract
Background: Review of the literature revealed several experimental studieson the effects of selective COX-2 inhibitors on fracture healing, but no reports were encountered regardingthe effects of these compounds on experimental heterotopic bone formation, so the present study was conducted.Material/Methods: Thirty adult male Wistar rats were divided into three groups of ten animals each. Tibialand femoral bones were collected from the rats, cleaned and demineralized, and diaphyseal parts wereimplanted in muscle pouches created in the right gluteal region, one into each rat. Group 1 receivedDFU (5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl)phenyl-2(5H)-furanone), a highly selectiveCOX-2 inhibitor, at a dose of 1.1 mg/kg/day. Group 2 received 2 mg/kg/day of indomethacin. The drugswere administered by oral gavage with 0.5% methyl cellulose as a delivery vehicle for eleven days, beginningon the first postoperative day. Group 3 received only methyl cellulose. Results: Thirty days after theimplantation of the demineralized bone matrix, 6/10 of DFU-treated, 9/9 of the indomethacin-treated,and 8/9 of the control rats displayed new bone formation. Conclusions: The results of this study suggestthat no form of non-steroidal anti-inflammatory drug has inhibitory effects on heterotopic bone formationin rats. In our opinion, bone formation is a quite complex process that requires several events and isregulated by several factors, so further investigations other than those using non-steroidal anti-inflammatorydrugs are required.
Keywords: Anti-Inflammatory Agents, Non-Steroidal - therapeutic use, Cyclooxygenase 2 Inhibitors - therapeutic use, Furans - therapeutic use, Indomethacin - therapeutic use, Ossification, Heterotopic - pathology, Rats, Wistar
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952